Reading MAIA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MAIA free→Reading MAIA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MAIA free→QuarterlyIQ Insights · MAIA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Termination of a Material Definitive Agreement. On May 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the Company and H.C. Wainwright & Co., LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the sales agreement, which termination wi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 27, 2026, the Board of Directors of MAIA Biotechnology, Inc. (the “Company”) approved one-time bonus payments of $312,610 to Vlad Vitoc, the Company’s Chief Executive Officer and $50,000 to Jeffrey Himmelreich, the Company’s Head of Finance, in consideration for their efforts in connection with the Company’s recent capital raise. The bonus…
Entry into a Material Definitive Agreement. On March 2, 2026, MAIA Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 20,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common S…
Other Events. On March 2, 2026, the Company issued a press release announcing the launch of the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On March 2, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. On March 4, 2026, the Company issu…
by reference. The Shares, the Warrants and the shares issuable upon exercise of the Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer t…
Other Events. On December 16, 2025, the Company issued a press release announcing the pricing of the Private Placement. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 16, 2025, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 1,053,751 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the…
by reference. The Investor Shares, the Investor Warrants and the shares issuable upon exercise of the Investor Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or a…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 13, 2025, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 603,769_shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ I…
Other Events. On October 13, 2025, the Company issued a press release announcing the pricing of the Private Placement. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. d) Exhibits. Exhibit No. Description 4.1 Form of Investor Warrant 10.1* Form of Securities Purchase Agreement 99.1 Press Release dated October 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * The schedules (and similar attachments) to this…
Other Events. On September 29, 2025, the Company issued a press release announcing the pricing of the Private Placement. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 29, 2025, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 1,714,536_shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the…
by reference. The Shares, the Warrants and the shares issuable upon exercise of the Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer t…
Unregistered Sales of Equity Securities The issuance of the Exercise Shares upon exercise of the Warrants will be issued pursuant to the exemption from registration provided by Section 4(a)(2), Rule 506 and/or 3(a)(9) of the Securities Act. The Company intends to use the proceeds received from the exercise of the Warrants described under
Entry into a Material Definitive Agreement. On September 18, 2025, MAIA Biotechnology, Inc, Inc. (the “ Company ”) entered into inducement offer letter agreements (the “ Inducement Letters ”) with (i) certain accredited investors (the “ Pre-IPO Participating Holders ”) that hold outstanding warrants to purchase up to an aggregate of 16,957 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) with an exercise price of $6.00 per share (the “ Pre-IPO Warrants…
Entry into a Material Definitive Agreement. On June 24, 2025, MAIA Biotechnology, Inc., a Delaware corporation (the “Corporation”) entered into a stock purchase agreement (“SPA”) with Prevail Partners, LLC (“Prevail”) under which it agreed to issue and sell $587,905 (the “Shares”) of the Corporation’s shares of common stock, par value $0.0001 per share (“Common Stock”) to Prevail, which Shares shall be paid as follows: (i) an upfront payment (the “Upfront Payment”) of $58,800.3333 of Shares (…
The Shares will be issued pursuant to the exemption from registration provided by Section 4(a)(2) and/or 3(a)(9) of the Securities Act of 1933, as amended. The use of proceeds will be used to pay for technologies and services provided by Prevail Infoworks, an affiliate of Prevail under that that certain Master Service and Technology Agreement (“MSTA”) dated September 24, 2024, and a Statement of Work (“SOW”) under MSTA, pursuant to which, the Company engaged InfoWorks to provide technologies…
Unregistered Sales of Equity Securities The issuance of the Exercise Shares upon exercise of the Warrants will be issued pursuant to the exemption from registration provided by Section 4(a)(2), Rule 506 and/or 3(a)(9) of the Securities Act. The Company intends to use the proceeds received from the exercise of the Warrants described under
Entry into a Material Definitive Agreement. On June 17, 2025, MAIA Biotechnology, Inc, Inc. (the “ Company ”) entered into inducement offer letter agreements (the “ Inducement Letters ”) with (i) certain accredited investors (the “ Pre-IPO Participating Holders ”) that hold outstanding warrants to purchase up to an aggregate of 61,510 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) with an exercise price of $6.00 per share (the “ Pre-IPO Warrants ”), o…
Entry into a Material Definitive Agreement. On May 27, 2025, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 429,999 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up…
Other Events. On May 27, 2025, the Company issued a press release announcing the pricing of the Private Placement. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. d) Exhibits. Exhibit No. Description 4.1 Form of Investor Warrant 4.2 Form of Director Warrant 10.1* Form of Securities Purchase Agreement 99.1 Press Release dated May 27, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * The schedules (and similar…
by reference. The Shares, the Warrants and the shares issuable upon exercise of the Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer t…
Entry into a Material Definitive Agreement. On April 14, 2025, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 633,333 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase…
by reference. The Shares, the Warrants and the shares issuable upon exercise of the Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder. 2 This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer…
Other Events. On May 5, 2025, the Company issued a press release announcing the pricing of the Private Placement. A copy of the press releases is attached as Exhibit 99.1 and is incorporated herein by reference. On May 5, 2025, the Company issued a corrective press release to correct he initial exercise date and term of the warrants purchased in the private placement. A copy of the corrective press release is attached as Exhibit 99.2 and incorporated herein by reference.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.